MaureenMeganO'BrienMD(She/Her)

Pediatric Hematology & Oncology • Aurora, CO

Pediatric Hematologic Oncology

Professor, University of Colorado School of Medicine, Children's Hospital Colorado

Join to view full profile

Dr. O'Brien is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Brien's full profile

Already have an account?

Office
13123 East 16th Avenue
Box B115
Aurora, CO 80045
Phone+1 720-777-6863

Fax+1 720-777-7227

Education & Training

Stanford University School of MedicineMS, Epidemiology, 2007 - 2008
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2004 - 2007
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2000 - 2003
Harvard Medical SchoolClass of 2000
Harvard UniversityAB, Biochemical Sciences, Summa Cum Laude, 1992 - 1996

Certifications & Licensure

CA State Medical License 2004 - Present
CO State Medical License 2023 - 2025
WY State Medical License 2024 - 2025
KY State Medical License 2021 - 2024
OH State Medical License 2009 - 2024
IN State Medical License 2021 - 2023
MA State Medical License 2003 - 2005
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2011 Apr 14
Completed
Phase 1
Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma Start of enrollment: 2012 Aug 01
Terminated
Early Phase 1
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20
Completed
Phase 2
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Start of enrollment: 2014 May 01
Completed
Phase 1
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Start of enrollment: 2021 Feb 24
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

16 citations
High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531.
Johann Hitzler, Todd A. Alonzo, Robert B. Gerbing, Amy Beckman, Betsy A. Hirsch
Blood. 2021-07-28
3 citations
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective
Jeremy D. Rubinstein, Rachana Shah, Erin H. Breese, Karen Burns, Jennifer Mangino
Pediatric Blood & Cancer. 2021-05-21
2 citations
Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
Maureen M. O'Brien, Todd A. Alonzo, Todd Cooper, John E. Levine, Patrick A. Brown
Pediatric Blood & Cancer. 2021-03-10

Abstracts/Posters

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...
Maureen M O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Maureen M O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
Maureen M O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Authored Content

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member